Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

7.26USD
21 Jul 2017
Change (% chg)

$-0.08 (-1.09%)
Prev Close
$7.34
Open
$7.38
Day's High
$7.39
Day's Low
$7.12
Volume
103,810
Avg. Vol
252,637
52-wk High
$25.11
52-wk Low
$5.91

Latest Key Developments (Source: Significant Developments)

Newlink Genetics ‍receives notice of allowance from USPTO covering indoximod salts and prodrugs​
Monday, 10 Jul 2017 07:00am EDT 

July 10 (Reuters) - Newlink Genetics Corp :Newlink Genetics says ‍receives notice of allowance from USPTO covering indoximod salts and prodrugs​.  Full Article

Great Point Partners reports 5.13 pct passive stake in Newlink Genetics
Monday, 5 Jun 2017 04:02pm EDT 

June 5 (Reuters) - Newlink Genetics Corp :Great Point Partners reports 5.13 percent passive stake in Newlink Genetics Corp as of May 26 - SEC filing.  Full Article

Newlink reports Results from clinical trial of indoximod plus chemotherapy
Friday, 2 Jun 2017 04:01pm EDT 

June 2 (Reuters) - Newlink Genetics Corp ::Results from clinical trial of indoximod plus chemotherapy for patients with metastatic breast cancer.Newlink Genetics Corp - ‍top line data from study show that trial did not meet its pre-specified endpoints​.Newlink Genetics Corp - ‍results from a phase 2 trial of indoximod in combination with taxane chemotherapy for patients with metastatic breast cancer​.  Full Article

Newlink Genetics loss of $0.72 per diluted share for Q1
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Newlink Genetics Corp :Newlink genetics reports first quarter 2017 financial results and updates clinical trial guidance.Net loss of $20.9 million or loss of $0.72 per diluted share for q1 of 2017.  Full Article

Newlink Genetics reports first quarter 2017 financial results
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Newlink Genetics Corp : :Newlink Genetics reports first quarter 2017 financial results and updates clinical trial guidance.Net loss of $20.9 million or loss of $0.72 per diluted share for Q1 of 2017.  Full Article

Newlink Genetics Q4 loss per share $0.46
Tuesday, 28 Feb 2017 08:00am EST 

Newlink Genetics Corp :Qtrly total revenue $12.7 million versus. $7.7 million, qtrly loss per share $0.46.  Full Article

Newlink Genetics Corp says it entered into a controlled equity offering(SM)sales agreement with Cantor Fitzgerald & Co
Tuesday, 29 Nov 2016 04:57pm EST 

Newlink Genetics Corp : Newlink Genetics Corp says on Nov 29, 2016 co entered into a controlled equity offering(SM)sales agreement with Cantor Fitzgerald & Co-SEC filing . Newlink Genetics - May offer and sell, through Cantor, shares of co's stock par value $0.01 per share, aggregate offering price of up to $40.0 million .Will pay Cantor a commission rate of up to 3.0% of aggregate gross proceeds from each sale of shares.  Full Article

Newlink Genetics Q2 loss per share $1.12
Friday, 29 Jul 2016 08:00am EDT 

Newlink Genetics Corp : Q2 loss per share $1.12 . Implemented a significant restructuring program following may results of impress phase 3 study of algenpantucel-l . Reducing headcount from approximately 230 to approximately 130 . Recorded $12.3 million in restructuring expenses in q2 . Winding down hyperacute cellular immunotherapy clinical trials that do not include a checkpoint inhibitor combination .In q3, company expects to record small additional charges relating to closing or reduction of leased facilities.  Full Article

Newlink Genetics elected to terminate Wuxi agreement
Monday, 6 Jun 2016 05:27pm EDT 

Newlink Genetics Corp: Elected to terminate Wuxi agreement . Determined to discontinue manufacturing operations for Algenpantucel-L and to terminate Wuxi agreement .Expects to make certain payments under outstanding work orders in connection with termination.  Full Article

Newlink Genetics announces results from phase 3 impress trial of Algenpantucel-L
Monday, 9 May 2016 04:01pm EDT 

Newlink Genetics : Impress phase 3 study of Algenpantucel-l for patients with resected pancreatic cancer did not achieve its primary endpoint . L for patients with resected pancreatic cancer did not achieve its primary endpoint . Overall survival from time of randomization was 29.3 months for both groups combined . There was also no statistical difference for long-term survival. . Newlink genetics corp says there was no statistically significant difference between two groups . "in light of these negative results, our scientific and clinical teams will focus on other promising opportunities in our pipeline" . Newlink genetics corp says reiterates that its goal and expectation is to finish 2016 with two years of cash on hand .L for patients with resected pancreatic cancer.  Full Article

BRIEF-Newlink Genetics ‍receives notice of allowance from USPTO covering indoximod salts and prodrugs​

* Newlink Genetics says ‍receives notice of allowance from USPTO covering indoximod salts and prodrugs​ Source text for Eikon: Further company coverage: